Holen Sie sich die Stockscreener-App
24.86
2.35%
0.57
Schlusskurs vom Vortag:
$24.29
Offen:
$24.03
24-Stunden-Volumen:
104.13K
Relative Volume:
0.62
Marktkapitalisierung:
$1.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-34.54
EPS:
-0.7198
Netto-Cashflow:
-
1W Leistung:
+3.41%
1M Leistung:
+16.01%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.63
$25.00
1-Wochen-Bereich:
$23.01
$26.46
52-Wochen-Spanne:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Firmenname
Seaport Therapeutics Inc
Sektor
Branche
Telefon
617-807-4062
Adresse
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
24.86 | 1.29B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Aktie (SPTX) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Trv Gp Vi LLC Purchases New Holdings in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.com.au
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics (SPTX) Institutional Ownership 2026 - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighTime to Buy? - MarketBeat
HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings - MarketBeat
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), Ethos Technologies Inc. Class A (LIFE) - The Globe and Mail
Seaport Therapeutics (SPTX): Daphne Zohar discloses 5.23M-share, 9.1% beneficial stake - Stock Titan
Seaport Therapeutics (SPTX) insider Steven M. Paul reports 6.3% stake - stocktitan.net
Seaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged - TipRanks
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright - MarketBeat
Seaport Therapeutics, Inc. 2026 Q2 Financials: Forward-Looking Statements, Risks, and Company Highlights - Minichart
Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX - Moomoo
Seaport Therapeutics reports Q2 2026 net loss $62.6M, $427.3M cash; advances GlyphAllo and GlyphAgo - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q2 Loss $1.78 a Share - marketscreener.com
Seaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary - TradingView
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Yahoo Finance
Seaport Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPTX - TradingView
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Michael Cunyuan Chen Net Worth (2026) - GuruFocus
Seaport Therapeutics, Inc. Revenue Breakdown – BOATS:SPTX - TradingView
Lana Gladstein Net Worth (2026) - GuruFocus
Enterprise value to EBITDA forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Q2 Earnings Forecast for SPTX Issued By HC Wainwright - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Seaport Therapeutics stock initiated at buy by H.C. Wainwright - Investing.com Canada
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - AOL.com
Wolfe Research Initiates Seaport Therapeutics(SPTX.US) With Hold Rating - Moomoo
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Price to sales forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Finanzdaten der Seaport Therapeutics Inc-Aktie (SPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seaport Therapeutics Inc-Aktie (SPTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):